Search research articles
Contact Us
Filters
Showing results (41-50 of 46) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 46 results.
Annals of the Rheumatic Diseases
|
September 20, 2007
Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study
M L Hetland, K Stengaard-Pedersen, P Junker, et al.
Scandinavian Journal of Rheumatology
|
September 11, 2014
Interactions between smoking, increased serum levels of anti-CCP antibodies, rheumatoid factors, and erosive joint disease in patients with early, untreated rheumatoid arthritis
A Krol, P Garred, N H H Heegaard, et al.
Scandinavian Journal of Rheumatology
|
August 29, 2013
Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression
T Ellingsen, I Hansen, J Thorsen, et al.
Annals of the Rheumatic Diseases
|
May 11, 2013
Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial
T W Jensen, M S Hansen, K Hørslev-Petersen, et al.
Annals of the Rheumatic Diseases
|
April 5, 2008
MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)
M L Hetland, B Ejbjerg, K Hørslev-Petersen, et al.
Scandinavian Journal of Rheumatology
|
November 4, 2016
Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)
S Møller-Bisgaard, B J Ejbjerg, I Eshed, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 46) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 46 results.
Annals of the Rheumatic Diseases
|
September 20, 2007
Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study
M L Hetland, K Stengaard-Pedersen, P Junker, et al.
Scandinavian Journal of Rheumatology
|
September 11, 2014
Interactions between smoking, increased serum levels of anti-CCP antibodies, rheumatoid factors, and erosive joint disease in patients with early, untreated rheumatoid arthritis
A Krol, P Garred, N H H Heegaard, et al.
Scandinavian Journal of Rheumatology
|
August 29, 2013
Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression
T Ellingsen, I Hansen, J Thorsen, et al.
Annals of the Rheumatic Diseases
|
May 11, 2013
Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial
T W Jensen, M S Hansen, K Hørslev-Petersen, et al.
Annals of the Rheumatic Diseases
|
April 5, 2008
MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)
M L Hetland, B Ejbjerg, K Hørslev-Petersen, et al.
Scandinavian Journal of Rheumatology
|
November 4, 2016
Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)
S Møller-Bisgaard, B J Ejbjerg, I Eshed, et al.
Page
of 5